Finally, little is currently known regarding potential roles in CRC progression for novel GEFs, e.g., ARHGEF12 and ARHGEF33, whose overexpression in CRC is associated with poor outcomes (Wu et al., 2023). This evidence concerns the gene ARHGEF33 and colorectal carcinoma.